Version 1
: Received: 1 October 2024 / Approved: 3 October 2024 / Online: 4 October 2024 (08:00:25 CEST)
How to cite:
Baindara, P.; Kumari, S.; Dinata, R.; Mandal, S. M. Antimicrobial Peptides in the Fight Against Drug-Resistant Superbug Infections. Preprints2024, 2024100241. https://doi.org/10.20944/preprints202410.0241.v1
Baindara, P.; Kumari, S.; Dinata, R.; Mandal, S. M. Antimicrobial Peptides in the Fight Against Drug-Resistant Superbug Infections. Preprints 2024, 2024100241. https://doi.org/10.20944/preprints202410.0241.v1
Baindara, P.; Kumari, S.; Dinata, R.; Mandal, S. M. Antimicrobial Peptides in the Fight Against Drug-Resistant Superbug Infections. Preprints2024, 2024100241. https://doi.org/10.20944/preprints202410.0241.v1
APA Style
Baindara, P., Kumari, S., Dinata, R., & Mandal, S. M. (2024). Antimicrobial Peptides in the Fight Against Drug-Resistant Superbug Infections. Preprints. https://doi.org/10.20944/preprints202410.0241.v1
Chicago/Turabian Style
Baindara, P., Roy Dinata and Santi M Mandal. 2024 "Antimicrobial Peptides in the Fight Against Drug-Resistant Superbug Infections" Preprints. https://doi.org/10.20944/preprints202410.0241.v1
Abstract
The discovery of antibiotics was one of the greatest achievements in human history, however, antibiotic resistance evolved no later than the introduction of antibiotics. The rapid evolution of antibiotic-resistant pathogens soon became a nightmare and remained a global healthcare threat. There is an urgent need to have new alternatives or new strategies to combat the multi-drug resistant superbugs such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant Pseudomonas aeruginosa (CR-PA), extended-spectrum β-lactamases (ESBL) bearing multidrug-resistant Acinetobacter baumannii (MDR-AB), Escherichia coli, and Klebsiella pneumonia. Antimicrobial peptides (AMPs) have been considered promising agents equipped with unique mechanisms of action along with several other benefits to fight the battle against drug-resistant superbugs. Overall, the current review summarizes the mechanisms of drug-resistant development, the mechanism of action adopted by AMPs to combat drug-resistant pathogens, and the immunomodulatory properties of AMPs. Additionally, we have also reviewed the synergistic potential of AMPs with conventional antibiotics and the associated challenges and limitations of AMPs in the way of pharmacological development for therapeutic applications in clinical settings.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
